MEGA GENOMICS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.79 HKD | +1.77% |
|
-2.00% | -4.95% |
| 03-26 | Mega Genomics Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 02-12 | Mega Genomics Stockholders to Vote March 1 on Continuing Transactions | MT |
| Sales 2022 | 146M 20.07M 157M 1.58B | Sales 2023 | 151M 20.84M 163M 1.64B | Capitalization | 2.23B 307M 2.39B 24.17B |
|---|---|---|---|---|---|
| Net income 2022 | -17M -2.34M -18.27M -185M | Net income 2023 | 30M 4.13M 32.25M 326M | EV / Sales 2022 | 16.1 x |
| Net cash position 2022 | 398M 54.76M 427M 4.32B | Net cash position 2023 | 478M 65.8M 513M 5.19B | EV / Sales 2023 | 11.6 x |
| P/E ratio 2022 |
-128
x | P/E ratio 2023 |
66
x | Employees | 229 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 52.29% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.77% | ||
| 1 week | -2.00% | ||
| Current month | -7.64% | ||
| 1 month | +6.30% | ||
| 3 months | +17.53% | ||
| 6 months | +23.46% | ||
| Current year | -4.95% |
1 week
9.34
10.10
1 month
9.0011.98
Current year
7.9612.40
1 year
7.6812.40
3 years
7.6821.00
5 years
7.6821.00
10 years
7.6821.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jing Jiang
CEO | Chief Executive Officer | 44 | - |
Xiang Yi
CTO | Chief Tech/Sci/R&D Officer | 44 | - |
Xia An
COO | Chief Operating Officer | 41 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Rong Yu
FOU | Founder | 52 | 21/04/21 |
Mei Ling Guo
BRD | Director/Board Member | 54 | 05/08/21 |
Lin Lin
CHM | Chairman | 48 | 21/04/21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 20/06/24 | 9.79 | +1.77% | 27 400 |
| 19/06/24 | 9.62 | -1.64% | 139,200 |
| 18/06/24 | 9.78 | -1.21% | 197,000 |
| 17/06/24 | 9.9 | +1.12% | 123,600 |
| 14/06/24 | 9.79 | -2.00% | 128,800 |
Delayed Quote Hong Kong S.E., June 20, 2024 at 09:08 am
More quotes
Mega Genomics Ltd is a China-based investment holding company principally engaged in genetic testing business. The Company operates its businesses through three segments. The Consumer Genetic Testing Services segment provides testing for nutrition and metabolism, cancer risk assessment, chronic disease susceptibility, pharmacogenetic testing and infectious disease testing. The Cancer Screening Services segment provides Septin9 colorectal cancer screening test, Syndecan-2 (SDC2) colorectal cancer screening test and ring finger protein 180 (RNF180)/Septin9 gastric cancer screening test. The Other Services segment provides genetic research and analysis services to third party research institutions.
Calendar
27/08/2024
- Q2 2024 Earnings Release (Projected)
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -4.95% | 291M | |
| -16.71% | 8.53B | |
| +67.76% | 4.31B | |
| +4.70% | 2.67B | |
| -2.63% | 2.62B | |
| -53.41% | 1.87B | |
| -19.59% | 1.66B | |
| -21.62% | 1.41B | |
| +16.16% | 1.2B | |
| -46.45% | 1.09B |
- Stock Market
- Equities
- 6667 Stock
